Cargando…
Apatinib inhibits gastric carcinoma development by regulating the expression levels of IL-17 via the Bax/Bcl-2 signaling pathway
Gastric carcinoma is a common type of gastrointestinal tumor with high morbidity and mortality rates. IL-17 is a newly discovered cytokine that has been reported to serve an important role in the development of gastric carcinoma. The potential effect of apatinib on IL-17 expression levels in the dev...
Autores principales: | Wang, Tianxi, Zhang, Jun, Cui, Lihong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097188/ https://www.ncbi.nlm.nih.gov/pubmed/33968184 http://dx.doi.org/10.3892/etm.2021.10086 |
Ejemplares similares
-
Apatinib inhibits the proliferation of gastric cancer cells via the AKT/GSK signaling pathway in vivo
por: Chen, Yi, et al.
Publicado: (2021) -
Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL-17
por: Chen, Ran, et al.
Publicado: (2019) -
Bcl-XL Inhibits Membrane Permeabilization by Competing with Bax
por: Billen, Lieven P, et al.
Publicado: (2008) -
Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?
por: Kulsoom, Bibi, et al.
Publicado: (2018) -
miR-21 regulates ischemic neuronal injury via the p53/Bcl-2/Bax signaling pathway
por: Yan, Honglin, et al.
Publicado: (2021)